1-4 of 4
Rosalyn Pham
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors

Mark Levis, Patrick Brown, B. Douglas Smith, Adam Stine, Rosalyn Pham, Richard Stone, Daniel DeAngelo, Ilene Galinsky, Frank Giles, Elihu Estey, Hagop Kantarjian, Pamela Cohen, Yanfeng Wang, Johannes Roesel, Judith E. Karp, Donald Small
Journal: Blood
Blood (2006) 108 (10): 3477–3483.
https://doi.org/10.1182/blood-2006-04-015743
Published: 2006
Journal Articles

Pharmacokinetic and Pharmacodynamic Studies of Lestaurtinib (CEP-701) and PKC-412: Cytotoxicity Is Often Dependent on Non-FLT3-Mediated Effects.

Mark Levis, MD, PhD, Adam Stine, BS, Rosalyn, Pham BS, B. Douglas Smith, MD, Judith Karp, MD, Richard Stone, MD, Elihu Estey, MD, Frank Giles, MD, Hagop Kantarjian, MD, Pamela Cohen, MD, Yanfeng Wang, PhD, Donald Small, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 2463.
https://doi.org/10.1182/blood.V106.11.2463.2463
Published: 2005
Journal Articles

Internal tandem duplications of the FLT3 gene are present in leukemia stem cells

Mark Levis, Kathleen M. Murphy, Rosalyn Pham, Kyu-Tae Kim, Adam Stine, Li Li, Ian McNiece, B. Douglas Smith, Donald Small
Journal: Blood
Blood (2005) 106 (2): 673–680.
https://doi.org/10.1182/blood-2004-05-1902
Published: 2005
Journal Articles

In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects

Mark Levis, Rosalyn Pham, B. Douglas Smith, Donald Small
Journal: Blood
Blood (2004) 104 (4): 1145–1150.
https://doi.org/10.1182/blood-2004-01-0388
Published: 2004